HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.